Related Experiment Video
Updated: Jun 20, 2026

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics
Published on: July 16, 2018
Extracellular proteases as targets for drug development
1Department of Biochemistry, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
Abstract:
Proteases constitute one of the primary targets in drug discovery. In the present review, we focus on extracellular proteases (ECPs) because of their differential expression in many pathophysiological processes, including cancer, cardiovascular conditions, and inflammatory, pulmonary, and periodontal diseases. Many new ECP inhibitors are currently under clinical investigation and a significant increase in new therapies based on protease inhibition can be expected in the coming years. In addition to directly blocking the activity of a targeted protease, one can take advantage of differential expression in disease states to selectively deliver therapeutic or imaging agents. Recent studies in targeted drug development for the metalloproteases (matrix metalloproteinases, adamalysins, pappalysins, neprilysin, angiotensin-converting enzyme, metallocarboxypeptidases, and glutamate carboxypeptidase II), serine proteases (elastase, coagulation factors, tissue/urokinase plasminogen activator system, kallikreins, tryptase, dipeptidyl peptidase IV) and cysteine proteases (cathepsin B) are discussed herein.
Insights
Extracellular proteases (ECPs) are key drug targets for diseases like cancer and inflammation. New therapies inhibiting ECPs or using them for targeted drug delivery are emerging.
Area of Science:
- Biochemistry
- Pharmacology
- Drug Discovery
Background:
- Proteases are crucial targets in drug discovery.
- Extracellular proteases (ECPs) are differentially expressed in various pathophysiological conditions, including cancer, cardiovascular, inflammatory, pulmonary, and periodontal diseases.
- This differential expression offers opportunities for targeted therapies and diagnostics.
Purpose of the Study:
- To review recent advancements in targeted drug development for extracellular proteases.
- To highlight the potential of ECP inhibitors and targeted delivery systems.
Main Methods:
- Review of current literature on extracellular proteases.
- Focus on metalloproteases, serine proteases, and cysteine proteases.
- Discussion of recent studies in targeted drug development.
Main Results:
- Numerous ECP inhibitors are in clinical trials.
- Significant growth in protease inhibition therapies is anticipated.
- Strategies include direct activity blockade and targeted delivery of agents.
Conclusions:
- Extracellular proteases represent a promising area for therapeutic intervention.
- Targeted drug development for ECPs is advancing rapidly.
- Future therapies will likely leverage ECP inhibition and targeted delivery for various diseases.
More Related Videos
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Role of Matrix Metalloproteases in Degradation of ECM
A...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
Caspases

